a new source of medical waste, and its carbon footprint is certainly not negligible considering the import from emergent countries. 9 Disposable blade in laryngoscopy seems presently well established in Languedoc-Roussillon. SUBs are a source of medical waste, thus this practice should be re-analysed in a spirit of sustainable development and risk-benefit balance. 
Sugammadex in a parturient with myotonic dystrophy
Editor-Myotonic dystrophy levior (Myotonia congenita levior-Thomsen 2, MCL), an autosomal-dominant disease bound to the chloride channel, is a chronic, slowly progressing, highly variable, inherited multisystemic disease. It is characterized by wasting of the muscles (muscular dystrophy), cataracts, heart conduction defects, endocrine changes, slow gastric and bowel emptying, and myotonia. Patients with myotonic dystrophy show myotonic responses to succinylcholine, 1 neostigmine, 2 and increased sensitivity to non-depolarizing neuromuscular blocking agents.
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The use of sugammadex, a novel drug developed specifically for the rapid reversal of neuromuscular block induced by steroidal non-depolarizing neuromuscular blocking agents, was reported in a patient with myasthenia gravis, 5 Huntington's disease, 6 and also in a woman with myotonic dystrophy.
7
We report a case of a woman, born in 1980, and diagnosed by a neurologist as having MCL at the age of 25. In the history, there was recorded cervical and low back pain. Physical examination showed the typical facies of myotonic dystrophy with athrophic sternocleidomastoid muscles. Most symptoms of MCL were in the lower limbs, but there was also myotonic reaction in upper arms and forearms. Muscle strength was symmetric. She suffered from paroxysmal tachycardia and the echocardiography showed mitral insufficiency with minimal haemodynamic significance. Her physical status was classified as ASA II.
In 2009 TOF 0.9 was achieved in 2 min. The patient was extubated without any complications and with full muscle strength. Postoperative care was provided in the recovery room for 2 h after operation and she was then transferred to the intermediate care unit of the obstetric department. No exacerbation of myotonia and no recurrence of muscle relaxation were observed perioperatively. On the fifth postoperative day, she was discharged. In this report, our patient with myotonic dystrophy showed normal recovery of the TOF ratio to 0.9 after the administration of sugammadex (4 mg kg 21 ) from deep blockade (TOF 0) in 2 min. She had normal sensitivity to rocuronium at induction (decrease to ST 10% in 50 s), prolonged duration of neuromuscular block induced with rocuronium Correspondence (up to 3 h after administration), and showed normal response to sugammadex.
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These two episodes in the same patient provide evidence for the benefits of sugammadex in patients with myotonic dystrophy.
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